|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 8/07/19 NovaBay Pharmaceuticals, Inc. 10-Q 6/30/19 92:8.8M RDG Filings/FA |
Document/Exhibit Description Pages Size
1: 10-Q Quarterly Report HTML 875K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 31K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 31K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 27K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 27K
12: R1 Document And Entity Information HTML 57K
13: R2 Consolidated Balance Sheets (Current Period HTML 110K
Unaudited)
14: R3 Consolidated Balance Sheets (Current Period HTML 47K
Unaudited) (Parentheticals)
15: R4 Consolidated Statements of Operations and HTML 89K
Comprehensive Loss (Unaudited)
16: R5 Consolidated Statements of Cash Flows (Unaudited) HTML 138K
17: R6 Consolidated Statements of Stockholders' Equity HTML 108K
(Unaudited)
18: R7 Note 1 - Organization HTML 40K
19: R8 Note 2 - Summary of Significant Accounting HTML 198K
Policies
20: R9 Note 3 - Fair Value Measurements HTML 115K
21: R10 Note 4 - Prepaid Expenses and Other Current Assets HTML 43K
22: R11 Note 5 - Inventory HTML 38K
23: R12 Note 6 - Property and Equipment HTML 45K
24: R13 Note 7 - Accrued Liabilities HTML 39K
25: R14 Note 8 - Commitments and Contingencies HTML 73K
26: R15 Note 9 - Related Party Notes Payable HTML 42K
27: R16 Note 10 - Convertible Note HTML 66K
28: R17 Note 11 - Warrant Liability HTML 101K
29: R18 Note 12 - Stockholders' Equity HTML 64K
30: R19 Note 13 - Equity-based Compensation HTML 135K
31: R20 Note 14 - License, Collaboration and Distribution HTML 78K
Agreements
32: R21 Note 15 - Employee Benefit Plan HTML 31K
33: R22 Note 16 - Related Party Transactions HTML 44K
34: R23 Note 17 - Subsequent Events HTML 41K
35: R24 Significant Accounting Policies (Policies) HTML 262K
36: R25 Note 2 - Summary of Significant Accounting HTML 119K
Policies (Tables)
37: R26 Note 3 - Fair Value Measurements (Tables) HTML 108K
38: R27 Note 4 - Prepaid Expenses and Other Current Assets HTML 43K
(Tables)
39: R28 Note 5 - Inventory (Tables) HTML 39K
40: R29 Note 6 - Property and Equipment (Tables) HTML 43K
41: R30 Note 7 - Accrued Liabilities (Tables) HTML 38K
42: R31 Note 8 - Commitments and Contingencies (Tables) HTML 62K
43: R32 Note 9 - Related Party Notes Payable (Tables) HTML 35K
44: R33 Note 10 - Convertible Note (Tables) HTML 54K
45: R34 Note 11 - Warrant Liability (Tables) HTML 92K
46: R35 Note 12 - Stockholders' Equity (Tables) HTML 43K
47: R36 Note 13 - Equity-based Compensation (Tables) HTML 102K
48: R37 Note 14 - License, Collaboration and Distribution HTML 53K
Agreements (Tables)
49: R38 Note 1 - Organization (Details Textual) HTML 31K
50: R39 Note 2 - Summary of Significant Accounting HTML 89K
Policies (Details Textual)
51: R40 Note 2 - Summary of Significant Accounting HTML 38K
Policies - Components of Cash, Cash Equivalents,
and Restricted Cash (Details)
52: R41 Note 2 - Summary of Significant Accounting HTML 42K
Policies - Revenues and Accounts Receivable From
Major Distribution Partners and Customers
(Details)
53: R42 Note 2 - Summary of Significant Accounting HTML 63K
Policies - Calculation of Basic and Diluted EPS
(Details)
54: R43 Note 2 - Summary of Significant Accounting HTML 32K
Policies - Outstanding Stock Options and Stock
Warrants Excluded From the Diluted Net Loss Per
Share Computation (Details)
55: R44 Note 2 - Summary of Significant Accounting HTML 50K
Policies - Impact of New Standard on Consolidated
Balance Sheet (Details)
56: R45 Note 3 - Fair Value Measurements (Details Textual) HTML 37K
57: R46 Note 3 - Fair Value Measurements - Assets and HTML 54K
Liabilities Measured at Fair Value on a Recurring
Basis (Details)
58: R47 Note 3 - Fair Value Measurements - Fair Value of HTML 36K
Warrant Liability (Details)
59: R48 Note 4 - Prepaid Expenses and Other Current Assets HTML 45K
- Summary of Prepaid Expenses and Other Current
Assets (Details)
60: R49 Note 5 - Inventory - Summary of Inventory HTML 37K
(Details)
61: R50 Note 6 - Property and Equipment (Details Textual) HTML 28K
62: R51 Note 6 - Property and Equipment - Summary of HTML 44K
Property and Equipment (Details)
63: R52 Note 7 - Accrued Liabilities - Summary of Accrued HTML 39K
Liabilities (Details)
64: R53 Note 8 - Commitments and Contingencies (Details HTML 36K
Textual)
65: R54 Note 8 - Commitments and Contingencies - Lease HTML 40K
Expense (Details)
66: R55 Note 8 - Commitments and Contingencies - Schedule HTML 47K
of Future Lease Payments (Details)
67: R56 Note 8 - Commitments and Contingencies - Schedule HTML 38K
of Future Lease Payments to Be Received (Details)
68: R57 Note 9 - Related Party Notes Payable (Details HTML 50K
Textual)
69: R58 Note 9 - Related Party Notes Payable - Schedule of HTML 46K
related Party Debt (Details)
70: R59 Note 10 - Convertible Note (Details Textual) HTML 74K
71: R60 Note 10 - Convertible Note - Key Assumptions Used HTML 34K
to Value the Combined Embedded Derivative
(Details)
72: R61 Note 10 - Convertible Note - Schedule of HTML 44K
Convertible Note (Details)
73: R62 Note 10 - Convertible Note - Schedule of Maturity HTML 39K
of Convertible Note (Details)
74: R63 Note 11 - Warrant Liability (Details Textual) HTML 128K
75: R64 Note 11 - Warrant Liability - The Key Assumptions HTML 54K
Used to Value the Warrants (Details)
76: R65 Note 11 - Warrant Liability - Outstanding Warrant HTML 37K
Liability (Details)
77: R66 Note 12 - Stockholders' Equity (Details Textual) HTML 163K
78: R67 Note 12 - Stockholders' Equity - Outstanding HTML 42K
Warrants (Details)
79: R68 Note 13 - Equity-based Compensation (Details HTML 156K
Textual)
80: R69 Note 13 - Equity-based Compensation - Stock HTML 93K
Options Outstanding (Details)
81: R70 Note 13 - Equity-based Compensation - HTML 40K
Weighted-average Assumptions Used in Determining
the Value of Options Granted to Employees and
Directors (Details)
82: R71 Note 13 - Equity-based Compensation - HTML 39K
Weighted-average Assumptions Used in Determining
the Value of Options Granted to Non-employees
(Details)
83: R72 Note 13 - Equity-based Compensation - Summary of HTML 35K
Stock-based Compensation Expense Included in
Results of Operations (Details)
84: R73 Note 14 - License, Collaboration and Distribution HTML 98K
Agreements (Details Textual)
85: R74 Note 14 - License, Collaboration and Distribution HTML 45K
Agreements - Changes in Assets and Liabilities
(Details)
86: R75 Note 14 - License, Collaboration and Distribution HTML 34K
Agreements - Total Revenues (Details)
87: R76 Note 15 - Employee Benefit Plan (Details Textual) HTML 28K
88: R77 Note 16 - Related Party Transactions (Details HTML 60K
Textual)
89: R78 Note 17 - Subsequent Events (Details Textual) HTML 42K
91: XML IDEA XML File -- Filing Summary XML 177K
90: EXCEL IDEA Workbook of Financial Reports XLSX 92K
6: EX-101.INS XBRL Instance -- nby-20190630 XML 2.60M
8: EX-101.CAL XBRL Calculations -- nby-20190630_cal XML 162K
9: EX-101.DEF XBRL Definitions -- nby-20190630_def XML 1.71M
10: EX-101.LAB XBRL Labels -- nby-20190630_lab XML 1.32M
11: EX-101.PRE XBRL Presentations -- nby-20190630_pre XML 1.74M
7: EX-101.SCH XBRL Schema -- nby-20190630 XSD 274K
92: ZIP XBRL Zipped Folder -- 0001437749-19-015688-xbrl Zip 232K
Exhibit 32.2
CERTIFICATION PURSUANT TO 18 U.S.C. §1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the quarterly report of NovaBay Pharmaceuticals, Inc. (the Company) on Form 10-Q for the quarter ended June 30, 2019 (the Report), I, Jason Raleigh, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: August 7, 2019
|
/s/ Jason Raleigh |
|
Chief Financial Officer
This Certification is made solely for the purpose of 18 USC Section 1350, subject to the knowledge standard contained therein, and not for any other purpose.
| This ‘10-Q’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 8/7/19 | 8-K | ||
| For Period end: | 6/30/19 | |||
| List all Filings | ||||